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The current conventional methods of introduc-
ing drugs into the systemic circulation include 
intravenous, intramuscular, or oral administra-
tion. Drug administration via the oral route can 
result in variable systemic levels of the active form 
of the drug, both within and among individuals, as 
a result of the variable abosrption or release of drug 
from the formulation , variation in pH of the 
gastrointestinal tract, differences in food intake, or 
initial entry of drug into the portal circulation. 
lnjections or infusions of drugs avoid some disad-
vantages of the oral route: however, neither of 
these forms of drug administration fills the need for 
prolonged unattended duration of drug availabil-
ity. Continuous infusion therapy is acknowledged 
as a superior mode of drug administration for 
certain conditions, and thus we have initially 
investigated the possibility of fulfilling such a need 
by using skin as a port of entry for continuous 
input of drugs into the systemic circulation . 
The skin is one of the most impenetrable tis ues 
of the body , for it functions as a barrier against 
invasion by microorganisms, viruses. and many 
toxic chemicals. and imultaneously limits the 
escape from the body of physiologically essential 
component such as water. As a result of its dual 
barrier role, skin has seldom been regarded as a 
suitable route for administration of drugs to the 
systemic circulation. Examination of the causes of 
skin impermeability. and of the factor which may 
modil\- it. has opened up approaches to using this 
organ as a route for administering medication to 
the systemic circulat ion and also has surfaced the 
poss ibility of optimizing therapy (with regard to 
drug concentration and time of exposure) for the 
treatment of topical disorders . 
Using human skin in vitro mounted as a mem-
brane in a permeation chamber, we have con-
firmed that for the drugs we have so far examined, 
the main factors that modify transdermal permea-
tion include: 
1. The stratum corneum, which is frequently as 
much as 5 orders of magnitude less permeable 
to most substances than the derm is and thus 
offers the p rincipal barrier to skin permeation 
[1). The skin appendages (sweat glands, hair 
follicles. sebaceous glands) in the human skin 
probably contribute little to sustained drug 
permeation through intact skin. 
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2. The physiochemical properties of the drug, 
such as its molecular size, pH, oil/water 
partition coefficient, and polarity [2J. 
3. The vehicle in which the drug is dissolved, 
which may modify the permeation of the drug 
through skin by affecting its release from the 
vehicle and subsequent partition into the 
stratum corneum. 
4. The physical form of the drug (ionized or 
non-ionized); the non-ionized form of a drug 
permeates more freely than the ionized. 
5. Hydration of the skin , which facilitates ab-
sorption and permeation of wat.er-soluble 
drugs. 
6. The lipid content of the skin. 
7. Use of sorption-promoting agents. 
8. Regional variations in skin properties. which 
result in modification of percutaneous ab-
sorption of drugs. 
The results of in vitro skin permeation experi-
ments designed to evaluate the importance of the 
above-mentioned factors , have indicated that it is 
feasible to administer drugs topically in a form 
such that the skin content of the drug is maximized 
(for topical therapy) or the skin content of the drug 
is minimized and maximum transdermal permea-
tion of drug is attained (for systemic therapy). 
We have initiated development of transdermal 
therapeutic systems which. when applied to the 
surface of intact skin. will deliver drugs continu-
ously and unattended to the systemic circulation 
at the appropriate predetermined rate. Knowledge 
of the factors which govern transdermal permea-
tion of a drug, including the vehicle of choice, etc., 
are built into the design of the system 0 that the 
drug is released from the system in a profile which 
will optimize the required therapeutic effect and 
elicit minimal unwanted side effects. 
The percutaneous absorption of certain of the 
drugs we have examined in vitro, using skin from 
human cadavers, has been followed in vivo. For the 
drugs ephedrine and scopolamine we find good 
agreement between percutaneous absorption in 
vitro and in vivo, indicating that for these two 
compounds there is little metabolism of the dr ug 
by the skin, and that cutaneous blood flow does not 
limit the appearance of drug in the systemic 
circulation. 
For scopolamine we have developed a transder-
mal therapeutic system which is a multilaminate 
structure of small size (up to 2.5 em 2 in area and 0.2 
mm thick) that can be worn comfortably at a fixed 
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location in the postauricular area, a region which 
provides for adequate drug permeability. 
The system has been designed to provide con-
trolled administration of scopolamine to the sur-
face of intact skin, such that the system controls 
the availability of drug to the systemic circulation , 
for prevention or t reatment of motion-induced 
nausea. The clinical data indicate that by control-
ling the systemic levels of this drug one can obtain 
a therapeutic effect and reduce the incidence and 
severity of unwanted parasympatholytic effects 
associated with the conventional forms of adminis-
tering this drug parenterally or orally. 
Scopolamine also produces a local effect at the 
site of application, namely, inhibition of sweat 
gland function. By changing the physical form of 
the drug presented to the skin surface and its 
pattern of administration, it is possible to maxi-
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mize this local effect of scopolamine and minimiz 
the throughput of drug to the systemic circulatior 
In conclusion, it now appears feasible to u, 
skin as a route of entry for drugs into the system 
circulation, such that we can provide controll~ I 
circulating levels of the drug lor up to one week . 
duration following a single application of a then 
peutic system. The concept of sustained delivery \ 
drugs at a predet.ermined rate for treatment. of top 
cal disorders requires controUed clinical pharmac( 
logic studies with each drug to define the optimu I 
pattern of drug administration required to elic . 
the desired therapeutic effect. 
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